Ignace Vergote
Katholieke Universiteit Leuven
H-index: 139
Europe-Belgium
Top articles of Ignace Vergote
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with … | Gynecologic Oncology | Debra L Richardson Kathleen N Moore Ignace Vergote Lucy Gilbert Lainie P Martin | 2024/6/1 |
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced … | International Journal of Gynecologic Cancer | Domenica Lorusso Marie-Ange Mouret-Reynier Philipp Harter Claire Cropet Cristina Caballero | 2024/4/1 |
1347 Prediction of lymph node metastasis in early-stage ovarian cancer: value of whole-body diffusion-weighted MRI | Kamiel Verbruggen Vincent Vandecaveye Ignace Vergote Toon Van Gorp Els Van Nieuwenhuysen | 2024/3/1 | |
Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal … | Philipp Harter Gerhard Bogner Luis Chiva David Cibula Nicole Concin | 2024/3/1 | |
Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in … | European Journal of Cancer | Antonio González-Martín Bhavana Pothuri Ignace Vergote Whitney Graybill Domenica Lorusso | 2023/8/1 |
Abstract PO5-21-10: Efficacy and Safety of Alpelisib in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor: An Open-label, Multi-centre … | Cancer Research | Rik Van Severen Anne-Sofie De Crem Hava Izci Laurence Slembrouck Isabelle Vanden Bempt | 2024/5/2 |
Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer | Giorgio Bogani Robert L Coleman Ignace Vergote Toon Van Gorp Isabelle Ray-Coquard | 2024/4/1 | |
907 Ovarian function after ovarian transposition prior to pelvic radiotherapy. A retrospective study | Charlotte Missotten Melissa Christiaens Toon Van Gorp Els Van Nieuwenhuysen Thaïs Baert | 2024/3/1 | |
368 Can morphology and immune infiltration predict the HRD status in newly diagnosed high grade serous ovarian carcinoma? Lessons from the PAOLA-1/ENGOT-Ov25 Trial, a GINECO study | Amel Kime Guillaume Bataillon Isabelle Treilleux Céline Callens Frédéric Selle | 2024/3/1 | |
Gene expression markers in peripheral blood and outcome in patients with platinum‐resistant ovarian cancer: A study of the European GANNET53 consortium | International Journal of Cancer | Eva Obermayr Thomas Mohr Eva Schuster Elena Ioana Braicu Eliane Taube | 2024 |
Best original research presented at the 24th European Congress on Gynaecological Oncology—Best of ESGO 2023 | Joanna Kacperczyk-Bartnik Nicolò Bizzarri Tibor Andrea Zwimpfer Houssein El Hajj Martina Aida Angeles | 2024/4/1 | |
Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer | Leukemia | Christopher Maximilian Arends Klara Kopp Raphael Hablesreiter Natalia Estrada Friederike Christen | 2024/4/18 |
778 Predictive value of whole-body diffusion-weighted MRI in the preoperative assessment of advanced ovarian cancer after neo-adjuvant chemotherapy | Vincent Vandecaveye Raphaëla Carmen Dresen Valerie Broeckhoven Thaïs Baert Els Van Nieuwenhuysen | 2024/3/1 | |
569 The Leuven PARPi benefit test as improved approach for prediction of PARPi benefit in the PAOLA-1/ENGOTov25 trial | Liselore Loverix Ignace Vergote Pieter Busschaert Tom Venken Philipp Harter | 2024/3/1 | |
Added value of serum proteins to clinical and ultrasound information in predicting the risk of malignancy in ovarian tumors | medRxiv | An Coosemans Jolien Ceusters Chiara Landolfo Thaïs Baert Wouter Froyman | 2024 |
Preclinical effects of Tumor Treating Fields (TTFields) with PARP inhibitors in ovarian cancer | Cancer Research | Yani Berckmans Hila Ene Kerem Ben-Meir Antonia Martinez-Conde Roni Monin | 2024/3/22 |
Olaparib Addition to Maintenance Bevacizumab Therapy in Ovarian Carcinoma With BRCA-Like Genomic Aberrations | JAMA Network Open | Philip C Schouten Sandra Schmidt Kerstin Becker Holger Thiele Peter Nürnberg | 2024/4/1 |
# 1350 Tumor treating fields (TTFields) therapy in platinum-resistant ovarian cancer: results from the ENGOT-ov50/GOG-3029/INNOVATE-3 phase 3 study | Ignace Vergote Larry Copeland Toon Van Gorp Annouschka Laenen Giovanni Scambia | 2024/3/1 | |
237 InnovaTV 301/ENGOT-Cx12/GOG-3057: a global, randomized, open-label, phase 3 study of tisotumab vedotin versus investigator’s choice of chemotherapy in 2L Or 3L recurrent or … | Antonio Gonzalez Martín Brian M Slomovitz Keiichi Fujiwara Elsa Kalbacher Andrea Bagameri | 2024/3/1 | |
Immunotherapy for advanced endometrial carcinoma: Time for a paradigm shift? | Belgian Journal of Medical Oncology | Christine Gennigens S Altintas JF Baurain H Denys S Henry | 2024 |
